Crystalline forms of IRAK degraders
The present disclosure relates generally to various forms, salts and compositions of compounds useful for the modulation of one or more interleukin-1 receptor-associated kinases ("IRAK") via ubiquitination and/or degradation and uses of the same in the treatment various diseases.
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
27.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure relates generally to various forms, salts and compositions of compounds useful for the modulation of one or more interleukin-1 receptor-associated kinases ("IRAK") via ubiquitination and/or degradation and uses of the same in the treatment various diseases. |
---|---|
Bibliography: | Application Number: US202117338420 |